Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis | Zendy

Kevin J. Downes | Zendy; Min Dong | Zendy; Tsuyoshi Fukuda | Zendy; John Clancy | Zendy; Christopher Haffner | Zendy; Michael Bennett | Zendy; Alexander A. Vinks | Zendy; Stuart L. Goldstein | Zendy

Open Access

Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis

Author(s) -

Kevin J. Downes,

Min Dong,

Tsuyoshi Fukuda,

John Clancy,

Christopher Haffner,

Michael Bennett,

Alexander A. Vinks,

Stuart L. Goldstein

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw351

Subject(s) - tobramycin , medicine , renal function , population , urinary system , cystic fibrosis , pharmacokinetics , urology , gentamicin , antibiotics , biology , environmental health , microbiology and biotechnology

Tobramycin is frequently used for treatment of bronchopneumonia in patients with cystic fibrosis (CF). Variability in tobramycin clearance (CL) is high in this population with few reliable approaches to guide dosing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research